Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy

By Christopher M. Overall, O. Kleifeld. Nature Reviews. Cancer, 2006

1,111 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/d7fa30c24ca9f0d1efcb46ccbec63a341e13e333

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. P. E. Van den Steen
2. J. Vandooren
3. G. Opdenakker
4. Erik Sahai
5. P. Steeg

In Molecular Biology

1. Erik Sahai
2. J. Vandooren
3. G. Opdenakker
4. P. E. Van den Steen
5. P. Steeg

In Oncology

1. Erik Sahai
2. J. Vandooren
3. G. Opdenakker
4. P. E. Van den Steen
5. P. Steeg

Citations in the corpus

• Illuminating the metastatic process (2007, result): “Therefore, the biochemical efficacy of MMP inhibitors does not translate into an effect on cell motility, and this may explain the poor results of MMP inhibitors in clinical trial”
• Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): The next decade (2013, background): “Cancer therapy with MMP inhibitors may also revive, when – with the aid of new technologies – a broader, wider and deeper picture of what happens in the tumor micro-environment is casted (Gerg et al., 2008; Krüger et al., 2010; Nakasone et al., 2012; Overall & Kleifeld, 2006).”
• Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases (2007, background): “Many small-molecular-mass inhibitors have been discovered and some of these have been evaluated for clinical use, but in general these seem to be unselective and to cause side effect”
• Tumor metastasis: mechanistic insights and clinical challenges (2006, background): “Besides the destruction of ECM, proteases liberate embedded growth factors and chemokines, activate latent proteins on the cell surface and may serve protective roles in tumorigenesi”
• Protease-dependent versus -independent cancer cell invasion programs: three-dimensional amoeboid movement revisited (2009, result): “The impact of silencing MT1-MMP alone on cancer cell–invasive activity stands in contrast with the failure of peptidomimetic MMP inhibitors (e.g., BB2516/marimastat) to exert beneficial effects in previously reported clinical cancer trails (Overall and Kleifeld, 2006).”